GMA-8011

Murine Anti- Factor VIII

Clone GMA-8011

Background

Factor VIII (FVIII) is a heterodimer consisting of a heavy chain (ranging in mass from 90 to 200 kDa) bound via metal ions to a light chain (80 kDa). In plasma, FVIII circulates in an inactive form bound to von Willebrand factor. Following activation by factor Xa or thrombin, factor VIIIa can function as cofactor for the enzyme factor IXa in the activation of factor X in the presence of phospholipid and Ca2+. Absent or defective FVIII is the cause of the X-linked recessive bleeding disorder hemophilia A. GMA-8011 (also known as 2A9 or 2A9.1B)1 recognizes the C1 domain of FVIII, inhibits FVIII activation and binding to VWF and phospholipids2, and displays subnanomolar binding to FVIII by surface plasmon resonance2.

More Information:

Product Datasheet, pdf

Description

Species Reactivity: Human
Source: Murine
Specificity: C1 domain
Immunogen: B-domain deleted recombinant Human Factor VIII
Isotype: IgG2a

Application

ELISA: Binds the C1 domain of recombinant human factor VIII in solid-phase ELISA.
Immunoblotting: Not recommended.
Inhibition: Weakly inhibitory in Bethesda assay.2

Purchase GMA-8011

  • 0.5 mg/$660.00
  • 0.1 mg/$265.00
For Larger Amounts Please Call:
(802) 865-6230
Quantity:
Continue Shopping

Antibody References:

  1. R.J. Summers et al. (2011). Blood. 117(11):3190-3198.
  2. G. Batsuli et al. (2016). Blood. 128(16): 2055-2067.
  3. J.M. Stewart et al. (2014). Xenotransplantation. 21(4):341–352.
  4. M.A. Zimmermann et al. (2014). Haemophilia. 20(3):e215-e221.
  5. J. Kahle et al. (2017). Blood. 130(6): 808–816.
  6. S. Krishnamoorthy et al. (2016). Cell Immunol. 301:30–39.
  7. M. Elnaggar et al. (2020). Molecular Therapy: Methods & Clinical Development. 17:1-12.